Aug. 15 at 12:34 AM
$ANNX I tried,but the answer is wishy-washy…
Sent them an email:
“Hi shareholder here,
I’m quite concerned about this new additional 24 month readout, can you tell me what proportion of the overall Type-I error is allocated to the Month-15 versus Month-24 primary analyses, and what is the resulting nominal significance threshold at each analysis?”
Thank you for your time”
Answer:
“Thank you for your questions. Given the strong study conduct, we have retained significant Phase 3-level power for the ARCHER II trial at both month 15 and month 24 timepoints, but we have not disclosed the details of the statistical plan. For further information, you can refer to the business update call held this week. https://ir.annexonbio.com/events/event-details/annexon-virtual-business-update-call”
